ARK Genomic Revolution ETF (BATS:ARKG) Reaches New 52-Week High – Should You Buy?

ARK Genomic Revolution ETF (BATS:ARKG) reached a new 52-week high during mid-day trading on Monday . The stock traded as high as $37.71 and last traded at $37.31, with a volume of 407026 shares. The stock had previously closed at $36.86.

ARK Genomic Revolution ETF Price Performance

The stock’s 50-day moving average is $31.72 and its 200 day moving average is $30.15.

Institutional Trading of ARK Genomic Revolution ETF

Institutional investors have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. boosted its stake in shares of ARK Genomic Revolution ETF by 30.6% during the fourth quarter. JPMorgan Chase & Co. now owns 5,149,454 shares of the company’s stock valued at $149,180,000 after acquiring an additional 1,205,541 shares during the last quarter. Morgan Stanley raised its stake in ARK Genomic Revolution ETF by 42.2% in the 4th quarter. Morgan Stanley now owns 4,025,965 shares of the company’s stock valued at $116,632,000 after purchasing an additional 1,193,795 shares during the last quarter. BNP Paribas Financial Markets raised its stake in ARK Genomic Revolution ETF by 49.7% in the 4th quarter. BNP Paribas Financial Markets now owns 3,514,980 shares of the company’s stock valued at $101,829,000 after purchasing an additional 1,167,558 shares during the last quarter. Wells Fargo & Company MN lifted its holdings in ARK Genomic Revolution ETF by 29.1% in the 4th quarter. Wells Fargo & Company MN now owns 1,287,390 shares of the company’s stock valued at $37,296,000 after purchasing an additional 290,301 shares in the last quarter. Finally, Royal Bank of Canada lifted its holdings in ARK Genomic Revolution ETF by 185.0% in the 4th quarter. Royal Bank of Canada now owns 445,592 shares of the company’s stock valued at $12,910,000 after purchasing an additional 289,237 shares in the last quarter.

ARK Genomic Revolution ETF Company Profile

The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.